Segments (Tables)

9 Months Ended

Sep. 30, 2013

Segment Reporting [Abstract]

Information regarding our geographic activities

Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:

	For the three months ended September 30,						For the nine months ended September 30,
(In thousands)	2013			2012			2013			2012
Product revenues:
Pharmaceuticals	$	16,563		$	11,495		$	50,708		$	30,051
Diagnostics	—			—			—			—
Corporate	—			—			—			—
	$	16,563		$	11,495		$	50,708		$	30,051
Revenue from services:
Pharmaceuticals	$	—		$	—		$	—		$	—
Diagnostics	2,710			43			8,870			173
Corporate	60			57			180			159
	$	2,770		$	100		$	9,050		$	332
Revenue from transfer of intellectual property:
Pharmaceuticals	$	913		$	—		$	14,720		$	—
Diagnostics	395			200			1,360			400
Corporate	—			—			—			—
	$	1,308		$	200		$	16,080		$	400
Operating (loss) income:
Pharmaceuticals	$	(11,126	)	$	(1,755	)	$	(7,171	)	$	(5,072	)
Diagnostics	(399		)	(3,810		)	(16,783		)	(12,835		)
Corporate	(6,606		)	(3,804		)	(17,393		)	(9,650		)
Less: Operating loss attributable to noncontrolling interests	(879		)	—			(2,419		)	—
	$	(19,010	)	$	(9,369	)	$	(43,766	)	$	(27,557	)
Depreciation and amortization:
Pharmaceuticals	$	2,020		$	1,780		$	5,417		$	4,805
Diagnostics	1,717			841			5,110			2,510
Corporate	31			44			121			132
	$	3,768		$	2,665		$	10,648		$	7,447
Revenues:
United States	$	4,078		$	300		$	25,130		$	732
Chile	7,993			6,781			24,216			19,669
Spain	4,026			1,997			13,503			1,997
Israel	3,099			1,516			9,666			4,661
Mexico	1,445			1,201			3,323			3,724
	$	20,641		$	11,795		$	75,838		$	30,783

(In thousands)	September 30, 2013		December 31, 2012
Assets:
Pharmaceuticals	$	1,087,950	$	142,299
Diagnostics	114,434		112,422
Corporate	180,598		35,109
	$	1,382,982	$	289,830
Goodwill:
Pharmaceuticals	$	174,734	$	32,844
Diagnostics	47,606		47,606
Corporate	—		—
	$	222,340	$	80,450